Continuous manufacturing has led to a paradigm shift in the production of OSD and is being widely adopted by many companies, including CDMO's (contract development and manufacturing organisations) and generics manufacturers.Mini Batch Blender
Image credit: Gericke
However, there are still some challenges that prevent CM being the go-to technology platform for low volume highly specialised potent drugs. Current methods for feeding and blending may not be suitable for running at low throughputs with very low share of active pharmaceutical ingredient (API).
Gericke have developed a novel semi continuous feeding and blending process, referred to as Mini Batch Blending, that combines the benefits of continuous manufacturing with the simplicity of a traditional batch process:
- Suitable for throughput rates below 1 kg/h and up to 20 kg/h without scale up
- Overall Batch sizes below 1 kg
- Suitable for drug loads below 1 percent
- Minimal use of API for process development especially during early phase development
- Simplify process control without start up or transient state
- Easy integration into existing process (e.g. tablet compression)
- Simplified control strategy without Residence Time Distribution RTD modelling
- Suitable for High Containment (OEB level 5)
The Gericke Mini Batch Blender is available as a standalone unit or fully integrated into the Gericke Formulation Skid (GFS) with Loss in Weight Feeders, Process Analytical Technology (PAT) and Material Handling.
Like all other Gericke equipment, the Gericke network of group companies and local partners globally supports these solutions. The Gericke test centres are available to select and verify the right mixing solution and the complete system setup. Furthermore, the Gericke Mini Batch Blender is available as a rental unit for on-site trials.
For more information visit the Gericke website, HERE.
The Global Miller
This blog is maintained by The Global Miller staff and is supported by the magazine Milling and Grain
which is published by Perendale Publishers Limited.
No comments:
Post a Comment